Skip to main content
. 2021 Dec 16;8:793040. doi: 10.3389/fmed.2021.793040

Figure 2.

Figure 2

MM-EV effect on HSPC viability. HSPC viability after 20 h of treatment with 200 μg and 400 μg of MM-derived EVs. Results are expressed as the percent of cell viability normalized to control. The bar graphs represent the average with standard deviation from three independent experiments; * indicates p < 0.05. MM, multiple myeloma; EVs, Extracellular vesicles; HSPC, hematopoietic stem and progenitor cells.